| 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|
| 营业收入(元) | |||
| 抗感染类(元) | 249,191,328.27 | 493,917,014.16 | 259,078,119.47 |
| 抗肿瘤类(元) | 385,645,742.73 | 631,182,232.62 | 334,222,414.39 |
| 慢性病类(元) | 218,131,786.61 | 323,394,343.76 | 155,369,553.15 |
| 消化类(元) | 124,242,162.66 | 269,902,610.08 | 145,636,980.99 |
| 其他(元) | 6,628,681.93 | 22,196,976.70 | 15,311,428.00 |
| 营业成本(元) | |||
| 抗感染类(元) | 39,759,997.19 | 87,487,679.82 | 47,509,385.29 |
| 抗肿瘤类(元) | 40,508,220.61 | 57,168,857.30 | 26,457,343.29 |
| 慢性病类(元) | 50,583,157.85 | 77,962,466.47 | 40,448,186.74 |
| 消化类(元) | 45,415,736.50 | 86,231,411.93 | 40,669,403.79 |
| 其他(元) | 3,195,843.28 | 9,194,358.27 | 5,919,394.73 |
| 毛利(元) | |||
| 抗感染类(元) | 209,431,331.08 | 406,429,334.34 | 211,568,734.18 |
| 抗肿瘤类(元) | 345,137,522.12 | 574,013,375.32 | 307,765,071.10 |
| 慢性病类(元) | 167,548,628.76 | 245,431,877.29 | 114,921,366.41 |
| 消化类(元) | 78,826,426.16 | 183,671,198.15 | 104,967,577.20 |
| 其他(元) | 3,432,838.65 | 13,002,618.43 | 9,392,033.27 |
| 毛利率(%) | |||
| 抗感染类(%) | 84.04 | 82.29 | 81.66 |
| 抗肿瘤类(%) | 89.50 | 90.94 | 92.08 |
| 慢性病类(%) | 76.81 | 75.89 | 73.97 |
| 消化类(%) | 63.45 | 68.05 | 72.07 |
| 其他(%) | 51.79 | 58.58 | 61.34 |
| 收入构成(%) | |||
| 抗感染类(%) | 25.33 | 28.38 | 28.48 |
| 抗肿瘤类(%) | 39.20 | 36.26 | 36.74 |
| 慢性病类(%) | 22.17 | 18.58 | 17.08 |
| 消化类(%) | 12.63 | 15.51 | 16.01 |
| 其他(%) | 0.67 | 1.28 | 1.68 |
| 毛利构成(%) | |||
| 抗感染类(%) | 26.04 | 28.57 | 28.26 |
| 抗肿瘤类(%) | 42.91 | 40.35 | 41.11 |
| 慢性病类(%) | 20.83 | 17.25 | 15.35 |
| 消化类(%) | 9.80 | 12.91 | 14.02 |
| 其他(%) | 0.43 | 0.91 | 1.25 |